MarketPulse

NATiV3 trial

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva's Cash Runway Extends to Mid-2027 as NATiV3 Phase 3 Trial Nears Completion

Clinical-stage biotech Inventiva reports €75M cash, €121.5M deposits in Q1 2026, with funding extending to mid-2027 pending warrant exercise.
IVAPhase 3 clinical trialMASH treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Banks on MASH Drug Data as Cash Runway Extends to 2027

Inventiva reports €196.5M liquidity with runway through mid-2027, awaiting Q4 2026 Phase 3 lanifibranor results for MASH treatment.
IVAcash positionclinical-stage biotech